0001209191-23-016935.txt : 20230307 0001209191-23-016935.hdr.sgml : 20230307 20230307180025 ACCESSION NUMBER: 0001209191-23-016935 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230303 FILED AS OF DATE: 20230307 DATE AS OF CHANGE: 20230307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daly Jason B. CENTRAL INDEX KEY: 0001906486 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 23714174 MAIL ADDRESS: STREET 1: 400 CROSSING BLVD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-03 0 0001723128 Amneal Pharmaceuticals, Inc. AMRX 0001906486 Daly Jason B. C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 0 1 0 0 SVP, Chief Legal Officer Class A Common Stock 2023-03-03 4 M 0 22645 A 22645 D Class A Common Stock 2023-03-03 4 F 0 8164 1.92 D 14481 D Restricted Stock Units 2023-03-03 4 M 0 22645 0.00 D Class A Common Stock 22645 67935 D Restricted Stock Units 2023-03-03 4 A 0 152905 0.00 A Class A Common Stock 152905 152905 D Performance-Based Restricted Stock Units 2023-03-03 4 A 0 305810 0.00 A Class A Common Stock 305810 305810 D Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units vest in four equal annual installments beginning on March 3, 2024. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 152,905 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. Exhibit 24-Power of Attorney /s/ Denis Butkovic, Attorney-in-Fact 2023-03-07 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents that the undersigned, does hereby make, constitute and appoint Denis Butkovic and Chris Daly as a true and lawful attorney-in-fact of the undersigned with full powers of substitution and revocation, for and in the name, place and stead of the undersigned (in the undersigned's individual capacity), to execute and deliver such forms that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Amneal Pharmaceuticals, Inc. pursuant to Sections 13(d), 13(g) and 16(a) of the Securities Exchange Act of 1934, as amended, including without limitation, Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5 (including any amendments thereto). The Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Schedule 13D, Schedule 13G, Forms 3, 4 and 5 with regard to his or her ownership of or transactions in securities of Amneal Pharmaceuticals, Inc., unless earlier revoked in writing. The undersigned acknowledges that Denis Butkovic and Chris Daly are not assuming any of the undersigned's responsibilities to comply with Section 13 or Section 16 of the Securities Exchange Act of 1934, as amended. By: /s/ Jason Daly Name: Jason Daly Date: February 22, 2023